CBD has lower affinity for CB receptors. It acts being an antagonist or partial antagonist at endogenous cannabinoid receptors (both equally CB1 and CB2 receptor kinds in addition to other G-protein-coupled receptors [GPCRs]) by inhibiting total binding of direct ligands, and will act largely at